+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liminal BioSciences Inc (LMNL) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 55 Pages
  • September 2022
  • GlobalData
  • ID: 4278568
Liminal BioSciences Inc (LMNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Liminal BioSciences Inc (Liminal), formerly ProMetic Life Sciences Inc, is a biopharmaceutical company that focuses on plasma-derived therapeutics and small-molecule drug development. The company develops products for the treatment of fibrosis, including respiratory, liver, and kidney diseases. Liminal develops drug candidates based on two drug discovery platforms: small molecule therapeutics (PSMT), and plasma-derived therapeutics. It intends to capitalize on its drug discovery platform and knowledge base to build an early-stage drug portfolio. The company owns research and development facilities in the UK, the US, and Canada, and has manufacturing facilities in Canada. Liminal is headquartered in Laval, Quebec, Canada.

Liminal BioSciences Inc Key Recent Developments

Sep 01, 2022: Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market
Aug 25, 2022: Liminal BioSciences announces termination of legacy CDMO contract
Aug 09, 2022: Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights
Jun 06, 2022: Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders
May 10, 2022: Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Liminal BioSciences Inc - Key Facts
  • Liminal BioSciences Inc - Key Employees
  • Liminal BioSciences Inc - Key Employee Biographies
  • Liminal BioSciences Inc - Major Products and Services
  • Liminal BioSciences Inc - History
  • Liminal BioSciences Inc - Company Statement
  • Liminal BioSciences Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Liminal BioSciences Inc - Business Description
  • Geographical Segment: Canada
  • Performance
  • Geographical Segment: The UK
  • Performance
  • R&D Overview
  • Liminal BioSciences Inc - Corporate Strategy
  • Liminal BioSciences Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Liminal BioSciences Inc - Strengths
  • Liminal BioSciences Inc - Weaknesses
  • Liminal BioSciences Inc - Opportunities
  • Liminal BioSciences Inc - Threats
  • Liminal BioSciences Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Liminal BioSciences Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 25, 2022: Liminal BioSciences announces termination of legacy CDMO contract
  • Aug 09, 2022: Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights
  • Jun 06, 2022: Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders
  • May 10, 2022: Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights
  • May 09, 2022: Liminal Biosciences to Present at Upcoming Investor Conferences
  • May 09, 2022: Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022
  • Apr 13, 2022: Liminal BioSciences Announces Annual Meeting of shareholders
  • Mar 17, 2022: Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results
  • Jan 19, 2022: Liminal BioSciences announces strategic priorities for 2022
  • Nov 15, 2021: Liminal BioSciences Reports Third Quarter 2021 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Liminal BioSciences Inc, Key Facts
  • Liminal BioSciences Inc, Key Employees
  • Liminal BioSciences Inc, Key Employee Biographies
  • Liminal BioSciences Inc, Major Products and Services
  • Liminal BioSciences Inc, History
  • Liminal BioSciences Inc, Other Locations
  • Liminal BioSciences Inc, Subsidiaries
  • Liminal BioSciences Inc, Key Competitors
  • Liminal BioSciences Inc, Annual Ratios
  • Liminal BioSciences Inc, Interim Ratios
  • Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Liminal BioSciences Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Liminal BioSciences Inc, Performance Chart (2017 - 2021)
  • Liminal BioSciences Inc, Ratio Charts
  • Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Liminal BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Eloxx Pharmaceuticals Inc
  • Transition Therapeutics Inc
  • Protokinetix Inc
  • Apotex Pharmachem Inc
  • Sterogene Bioseparations Inc